VKTX

Viking Therapeutics, Inc.

37.54 USD
+0.12 (+0.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Viking Therapeutics, Inc. stock is up 74.52% since 30 days ago. The next earnings date is Apr 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 20:37 19 Apr, 2024 50.00 CALL 41 1492
23 Feb 14:32 15 Mar, 2024 36.00 CALL 60 356
23 Feb 15:50 17 Jan, 2025 35.00 CALL 20 351
23 Feb 16:59 15 Mar, 2024 40.00 CALL 129 2829
23 Feb 17:08 17 Jan, 2025 20.00 CALL 100 1136
23 Feb 17:57 15 Mar, 2024 48.00 CALL 200 6383
23 Feb 19:30 17 May, 2024 35.00 CALL 50 1248
23 Feb 20:23 15 Mar, 2024 44.00 CALL 150 3105
23 Feb 20:25 15 Mar, 2024 29.00 PUT 147 110
23 Feb 20:51 15 Mar, 2024 40.00 CALL 112 2829

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

  • Stifel
    Wed Feb 14, 09:09
    buy
    confirm
  • Maxim Group
    Thu Feb 8, 14:24
    buy
    confirm